Path ID: DB08870_MESH_D006689_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C547738 | brentuximab vedotin | Drug |
| UniProt:P28908 | Tumor necrosis factor receptor superfamily member 8 | Protein |
| CL:0001063 | tumor cell | Cell |
| MESH:C495575 | monomethyl auristatin E | ChemicalSubstance |
| GO:0008219 | Cell death | BiologicalProcess |
| MESH:D006689 | Hodgkin’s disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Brentuximab Vedotin | MOLECULARLY INTERACTS WITH | Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Tumor Necrosis Factor Receptor Superfamily Member 8 | EXPRESSED IN | Tumor Cell |
| Brentuximab Vedotin | COEXISTS WITH | Monomethyl Auristatin E |
| Monomethyl Auristatin E | CAUSES | Cell Death |
| Tumor Cell | ENABLES | Cell Death |
| Cell Death | NEGATIVELY CORRELATED WITH | Hodgkin’S Disease |
Comment: Brentuximab vedotin is anantibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE)
Reference: